Key Points Industry/Company - Company: Moderna, Inc. (NASDAQ:MRNA) - Industry: Biotechnology, mRNA medicine Core Points and Evidence - Mission: To deliver the greatest possible impact to people through mRNA medicine. - Platform: Moderna's mRNA platform allows for the creation of multiple medicines for various diseases. - Pipeline: Several medicines in development for 2024 and 2025, including vaccines, cancer, and rare genetic diseases. - Disease X: Moderna is preparing for a potential next pandemic with mRNA access, a tool to create an ecosystem for collaboration with scientists worldwide. - Environmental Goals: Net zero carbon emissions for Scope 1 and 2 by 2030. - Employee Focus: Attracting and retaining top talent, fostering a diverse and inclusive culture, and providing employee benefits and development opportunities. - Community Engagement: Employee volunteering programs, philanthropic giving, and partnerships with NGOs. - Governance and Ethics: Strong governance practices, ethical business conduct, and transparency in ESG reporting. Other Important Points - Rare Diseases: Moderna's mRNA platform has shown promise in treating rare diseases, with several programs demonstrating positive results. - Health Equity: Moderna is committed to inclusive research and ensuring that clinical trials represent diverse populations. - Pandemic Preparedness: Moderna's mRNA platform has been instrumental in developing the COVID-19 vaccine and is being used to prepare for future pandemics. - Global Health Portfolio: Includes vaccines for COVID-19, Zika, Chikungunya, HIV, and pandemic influenza. - mRNA Access Program: Collaborates with academic institutions worldwide to develop mRNA vaccines against emerging and neglected infectious diseases. - Sustainability: Moderna is committed to sustainability by design, resource conservation, and decarbonizing its value chain. - Employee Engagement: Moderna focuses on employee engagement, culture, and well-being through various programs and initiatives. - Community Impact: Moderna's community programs focus on education, health, and social justice. - Governance: Moderna's board of directors and executive committee are committed to ESG oversight and accountability. References - [doc id='3'] - [doc id='5'] - [doc id='7'] - [doc id='8'] - [doc id='9'] - [doc id='10'] - [doc id='12'] - [doc id='13'] - [doc id='14'] - [doc id='15'] - [doc id='16'] - [doc id='17'] - [doc id='18'] - [doc id='19'] - [doc id='20'] - [doc id='21'] - [doc id='22'] - [doc id='23'] - [doc id='24'] - [doc id='25'] - [doc id='26'] - [doc id='27'] - [doc id='28'] - [doc id='29'] - [doc id='30'] - [doc id='31'] - [doc id='32'] - [doc id='33'] - [doc id='34'] - [doc id='35'] - [doc id='36'] - [doc id='37'] - [doc id='38'] - [doc id='39'] - [doc id='40'] - [doc id='41'] - [doc id='42'] - [doc id='43'] - [doc id='44'] - [doc id='45'] - [doc id='46'] - [doc id='47'] - [doc id='48'] - [doc id='49'] - [doc id='50'] - [doc id='51'] - [doc id='52'] - [doc id='53'] - [doc id='54'] - [doc id='55'] - [doc id='56'] - [doc id='57'] - [doc id='58'] - [doc id='59'] - [doc id='60'] - [doc id='61'] - [doc id='62'] - [doc id='63'] - [doc id='64'] - [doc id='65'] - [doc id='66'] - [doc id='67'] - [doc id='68'] - [doc id='69'] - [doc id='70'] - [doc id='71'] - [doc id='72'] - [doc id='73'] - [doc id='74'] - [doc id='75'] - [doc id='76'] - [doc id='77'] - [doc id='78'] - [doc id='79'] - [doc id='80'] - [doc id='81'] - [doc id='82'] - [doc id='83'] - [doc id='84'] - [doc id='85'] - [doc id='86'] - [doc id='87'] - [doc id='88'] - [doc id='89'] - [doc id='90'] - [doc id='91'] - [doc id='92'] - [doc id='93'] - [doc id='94'] - [doc id='95'] - [doc id='96'] - [doc id='97'] - [doc id='98'] - [doc id='99'] - [doc id='100'] - [doc id='101'] - [doc id='102'] - [doc id='103'] - [doc id='104'] - [doc id='105'] - [doc id='106'] - [doc id='107'] - [doc id='108'] - [doc id='109'] - [doc id='110'] - [doc id='111'] - [doc id='112'] - [doc id='113'] - [doc id='114'] - [doc id='115'] - [doc id='116'] - [doc id='117'] - [doc id='118'] - [doc id='119'] - [doc id='120'] - [doc id='121'] - [doc id='122'] - [doc id='123'] - [doc id='124'] - [doc id='125'] - [doc id='126'] - [doc id='127']
Moderna, Inc. (MRNA) 2023 ESG Day Conference (Transcript)
Moderna(MRNA)2023-12-07 19:54